TWI853841B - 尼拉帕尼（niraparib）鹽 - Google Patents
尼拉帕尼（niraparib）鹽 Download PDFInfo
- Publication number
- TWI853841B TWI853841B TW108135909A TW108135909A TWI853841B TW I853841 B TWI853841 B TW I853841B TW 108135909 A TW108135909 A TW 108135909A TW 108135909 A TW108135909 A TW 108135909A TW I853841 B TWI853841 B TW I853841B
- Authority
- TW
- Taiwan
- Prior art keywords
- niraparib
- crystalline form
- salt
- indazole
- piperidin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Transplantation (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862740872P | 2018-10-03 | 2018-10-03 | |
| US62/740,872 | 2018-10-03 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW202028181A TW202028181A (zh) | 2020-08-01 |
| TWI853841B true TWI853841B (zh) | 2024-09-01 |
Family
ID=68345029
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW108135909A TWI853841B (zh) | 2018-10-03 | 2019-10-03 | 尼拉帕尼（niraparib）鹽 |
| TW113130597A TW202513550A (zh) | 2018-10-03 | 2019-10-03 | 尼拉帕尼（niraparib）鹽 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW113130597A TW202513550A (zh) | 2018-10-03 | 2019-10-03 | 尼拉帕尼（niraparib）鹽 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP3860981B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP7472115B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR20210071022A (cg-RX-API-DMAC10.html) |
| CN (2) | CN113166071B (cg-RX-API-DMAC10.html) |
| ES (1) | ES2967517T3 (cg-RX-API-DMAC10.html) |
| TW (2) | TWI853841B (cg-RX-API-DMAC10.html) |
| WO (1) | WO2020072797A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023524794A (ja) | 2020-05-08 | 2023-06-13 | ヤンセン ファーマシューティカ エヌ．ベー． | アビラテロン酢酸エステルとニラパリブの組み合わせによる前立腺癌の処置 |
| US20240325369A1 (en) | 2021-07-19 | 2024-10-03 | Janssen Pharmaceutica Nv | Treatment of metastatic castration-resistant prostate cancer with niraparib |
| JP2026517228A (ja) | 2023-05-17 | 2026-05-28 | テサロ， インコーポレイテッド | がんの治療におけるポリａｄｐリボースポリメラーゼ（ｐａｒｐ）阻害剤の新規使用 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE640616A (cg-RX-API-DMAC10.html) | 1962-12-19 | |||
| US3492397A (en) | 1967-04-07 | 1970-01-27 | Warner Lambert Pharmaceutical | Sustained release dosage in the pellet form and process thereof |
| US4060598A (en) | 1967-06-28 | 1977-11-29 | Boehringer Mannheim G.M.B.H. | Tablets coated with aqueous resin dispersions |
| US3538214A (en) | 1969-04-22 | 1970-11-03 | Merck & Co Inc | Controlled release medicinal tablets |
| US4173626A (en) | 1978-12-11 | 1979-11-06 | Merck & Co., Inc. | Sustained release indomethacin |
| EP2240466B1 (en) | 2008-01-08 | 2015-07-29 | Merck Sharp & Dohme Limited | Pharmaceutically acceptable salts of 2-{4-[(3s)-piperidin-3- yl]phenyl} -2h-indazole-7-carboxamide |
| EP2928473B1 (en) | 2012-12-07 | 2017-06-28 | Merck Sharp & Dohme Corp. | Regioselective n-2 arylation of indazoles |
| RS61400B1 (sr) | 2013-05-02 | 2021-02-26 | Anaptysbio Inc | Antitela usmerena protiv programirane smrti-1 (pd-1) |
| MA41463A (fr) | 2015-02-03 | 2017-12-12 | Anaptysbio Inc | Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3) |
| PL3277321T3 (pl) | 2015-04-01 | 2024-11-18 | Anaptysbio, Inc. | Przeciwciała skierowane przeciwko białku 3 immunoglobuliny limfocytów t i mucyny (tim-3) |
| HRP20240136T1 (hr) | 2016-06-29 | 2024-04-12 | Tesaro, Inc. | Metode liječenja raka jajnika |
| CN110049777A (zh) | 2016-11-01 | 2019-07-23 | 安奈普泰斯生物有限公司 | 针对程序性死亡-1(pd-1)的抗体 |
| MA50677A (fr) | 2016-11-01 | 2021-07-14 | Anaptysbio Inc | Anticorps dirigés contre la protéine d'immunoglobuline de lymphocytes t et mucine 3 (tim-3) |
| CN108201537A (zh) | 2016-12-16 | 2018-06-26 | 苏州苏融生物医药有限公司 | 一种尼拉帕尼缓控释药物组合物及其用途 |
| WO2018122168A1 (en) * | 2016-12-29 | 2018-07-05 | Bayer Pharma Aktiengesellschaft | Combinations of bub1 kinase and parp inhibitors |
| PT3565844T (pt) | 2017-01-09 | 2023-05-02 | Tesaro Inc | Métodos de tratamento de cancro com anticorpos anti-pd-1 |
| AU2018205401B2 (en) | 2017-01-09 | 2025-01-02 | Tesaro, Inc. | Methods of treating cancer with anti-TIM-3 antibodies |
| CN108203404A (zh) * | 2018-03-02 | 2018-06-26 | 上海博邦医药科技有限公司 | (r)-3-苯基哌啶或/和(s)-3-苯基哌啶以及尼拉帕尼的手性中间体的合成方法 |
-
2019
- 2019-10-03 CN CN201980078366.1A patent/CN113166071B/zh active Active
- 2019-10-03 EP EP19794786.4A patent/EP3860981B1/en active Active
- 2019-10-03 KR KR1020217012838A patent/KR20210071022A/ko active Pending
- 2019-10-03 TW TW108135909A patent/TWI853841B/zh active
- 2019-10-03 ES ES19794786T patent/ES2967517T3/es active Active
- 2019-10-03 CN CN202411070879.7A patent/CN118994103A/zh active Pending
- 2019-10-03 TW TW113130597A patent/TW202513550A/zh unknown
- 2019-10-03 JP JP2021518561A patent/JP7472115B2/ja active Active
- 2019-10-03 WO PCT/US2019/054534 patent/WO2020072797A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022504236A (ja) | 2022-01-13 |
| TW202028181A (zh) | 2020-08-01 |
| CN113166071A (zh) | 2021-07-23 |
| CN113166071B (zh) | 2025-03-21 |
| TW202513550A (zh) | 2025-04-01 |
| EP3860981A1 (en) | 2021-08-11 |
| ES2967517T3 (es) | 2024-04-30 |
| EP3860981B1 (en) | 2023-11-29 |
| CN118994103A (zh) | 2024-11-22 |
| WO2020072797A1 (en) | 2020-04-09 |
| KR20210071022A (ko) | 2021-06-15 |
| JP7472115B2 (ja) | 2024-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6763919B2 (ja) | Ｄｎａ−ｐｋ阻害剤としての（ｓ）−ｎ−メチル−８−（１−（（２’−メチル−［４，５’−ビピリミジン］−６−イル）アミノ）プロパン−２−イル）キノリン−４−カルボキサミドおよびその重水素化誘導体の共結晶 | |
| TWI633103B (zh) | 選擇性ｃｄｋ４／６抑制劑之固態形式 | |
| CN102245023B (zh) | 取代的二氧代哌啶基邻苯二甲酰亚胺衍生物 | |
| CA3210612C (en) | Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide | |
| JP2024537795A (ja) | ヘテロ芳香族大環状エーテル化合物の固体形態、薬学的組成物、及び調製 | |
| JP7472115B2 (ja) | ニラパリブ塩 | |
| KR20250012083A (ko) | 피페리딘일-메틸-푸린 아민 d-타르타르산 염, 결정질 형태 및 의학적 질환 및 병태 치료에서의 이들의 용도 | |
| US12297184B2 (en) | Niraparib salts | |
| CN108699083A (zh) | 喹啉酮类似物及其盐的结晶形式 | |
| JP2025541228A (ja) | ピペリジニル－メチル－プリンアミンを含有する医薬組成物ならびに疾患及び状態の治療におけるその使用 | |
| TW202542127A (zh) | 激酶抑制劑之固態形式 | |
| CN115671295A (zh) | 包含化合物的药物组合物及其使用方法 | |
| JP2017529356A (ja) | チロシンキナーゼ阻害剤及びその塩の結晶形態 | |
| TW201008923A (en) | Novel salt | |
| JP2023502969A (ja) | ＭｅｒＴＫおよびＴＹＲＯ３の二重阻害剤としてのアリールアミノピリミジンおよびその方法 | |
| TW202115091A (zh) | 喹啉類似物之結晶型及其鹽類、組合物、及彼等之使用方法 | |
| HK40120176A (en) | Niraparib salts | |
| HK40048853A (en) | Niraparib salts | |
| HK40048853B (en) | Niraparib salts | |
| CN113543779A (zh) | 使用6,8-双-苄硫基-辛酸的口服疗法 | |
| TW202409035A (zh) | Akr1c3依賴性kars抑制劑的晶型 | |
| TWI765848B (zh) | 喹諾酮類似物及其鹽的結晶形式 | |
| HK40107073A (en) | Pi3k inhibitors, nanoformulations, and uses thereof | |
| TW201136935A (en) | Salts of an indazolylpyrrolotriazine |